Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Slideshows|November 18, 2019
RA Clinical Quiz: Should therapy be tapered?
In today's installment of the rheumatoid arthritis clinical quiz, we examine treatment options for patients with established disease. Is sustained treatment with csDMARDs preferred over reducing the dose or dosing frequency of treatment? Click on the slideshow for more information.
Advertisement
In today's installment of the rheumatoid arthritis clinical quiz, we examine treatment options for patients with established disease. Is sustained treatment with csDMARDs preferred over reducing the dose or dosing frequency of treatment? Click on the slideshow for more information.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement